Genome-based pharmacogenetics and the pharmaceutical industry
- 1 July 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 1 (7) , 541-549
- https://doi.org/10.1038/nrd840
Abstract
Pharmacogenetic capabilities have changed markedly since The SNP Consortium made a dense single-nucleotide polymorphism (SNP) map freely available in 2001. For more than 40 years, pharmacokinetics and pharmacodynamics of drug-metabolizing molecules were the focus of practical applications. Today, it is possible to use SNP-mapping technologies to create a genetic profile of each individual that can be used to identify patterns of susceptibility genes for common diseases as well as genetic risk/efficacy factors that are related to the effects of drugs.Keywords
This publication has 43 references indexed in Scilit:
- Patterns of linkage disequilibrium in the human genomeNature Reviews Genetics, 2002
- Identification of a Psoriasis Susceptibility Candidate Gene by Linkage Disequilibrium Mapping with a Localized Single Nucleotide Polymorphism MapGenomics, 2002
- Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug ResponseAnnual Review of Genomics and Human Genetics, 2001
- Pharmacogenomics: Unlocking the Human Genome for Better Drug TherapyAnnual Review of Pharmacology and Toxicology, 2001
- Science, medicine, and the future: PharmacogeneticsBMJ, 2000
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- A 4-Mb High-Density Single Nucleotide Polymorphism-Based Map around Human APOEGenomics, 1998
- AbacavirDrugs, 1998
- APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASEAnnual Review of Medicine, 1996
- Pharmacogenetics and ecogenetics in 1991Pharmacogenetics, 1991